Predominantly, the high prevalence of tuberculosis in underdeveloped and poor countries spells growth in the pyrazinamide market. Pyrazinamide is an important element of multidrug therapy for tuberculosis. According to statistics of the World Health Organization, tuberculosis is one of the leading causes of death across the world. In 2019, nearly 10 mn people were affected by tuberculosis, say published statistics. Moreover, tuberculosis counts as the leading cause of death related to a single infectious force.
Get Sample Copy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7109
For the treatment of tuberculosis, pyrazinamide is used as an additive in various drugs. Pyrazinamide is an antibiotic that works by killing or eliminating the growth of tuberculosis-causing bacteria. Pyrazinamide is generally consumed orally in tablet form.
For the treatment of active tuberculosis, pyrazinamide is often used with isoniazid, rifampicin or with ethambutol or streptomycin. Meanwhile, pyrazinamide is not recommended for the treatment of latent tuberculosis.
Government initiatives to eradicate tuberculosis spells growth
Government initiatives in several countries to eliminate tuberculosis continues to spell growth in the pyrazinamide market. For example, in India, the government has set a target to eradicate tuberculosis in the country by 2025.
In terms of chemical composition, pyrazinamide is a synthetic derivative of pyrazinoic acid amide. With bactericidal properties. In particular, pyrazinamide is active against slow multiplying intracellular bacilli that are unaffected by other drugs. It does so by an unknown mechanism of action.
Moreover, the bacterial action of pyrazinamide is dependent on the presence of bacterial pyrazinamidase. Bacterial pyrazinamidase in pyrazinamide eliminates the amide group to produce active pyrazinoic acid.
Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7109
Pyrazinamide holds significance for other reasons too. It is the first line of antituberculosis medication, but is used only in combination with other medications such as rifampin or isoniazid.
The pyrazinamide market is a choc-o-bloc with companies of varying sizes in the fray. Extensive R&D for new drug formulations is a key focus of large players in the pyrazinamide market. Savvy players are also engaging in inorganic growth strategies to stay competitive in the pyrazinamide market.